Epidemiology and risk factors of cardiovascular disease in postmenopausal women

Menopause

Volumn , Issue , 2007, Pages 405-452

  Zev Gorodeski, Elran ^a   Gorodeski, George I ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882908683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50039-9     Document Type: Chapter

References (391)

1. Kochanek KD, Murphy SL, Anderson RN, Scott C Deaths: final data for 2002. National Vital Statistics Report CDC 2004, 53:1-115.
2. National Heart Lung Blood Institute Tabulations of the National Health Interview Survey. National Center for Health Statistics 2005, Accessed June, 15, from. http://www.cdc.gov/nchs/datawh/ftpservJftpdata/ftpdata.htm.
3. National Ambulatory Medical Care Survey, 2001-2002 Summary, CDC/NCHS.
4. Watkins LO Perspectives on coronary heart disease in African Americans. Rev Cardiovasc Med 2004, 5:S3-S13.
5. Heart Disease and Stroke Statistics: 2005 update. Accessed June, 15, 2005, from www.americanheart.org.
6. Peeters A, Mamun AA, Willekens F, Bonneux L A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002, 23:458-466.
7. Mosca L, Jones WK, King KB, et al. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. Arch Fam Med 2000, 9:506-515.
8. Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994, 120:559-566.
9. Schrott HG, Bittner V, Vittinghoff E, et al. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Re-placement. J Am Med Assoc 1997, 277:1281-1286.
10. Miller M, Byington R, Hunninghake D, et al. Sex bias and underuti-lization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000, 160:343-347.
11. Malek AM, Alper SL, Izumo S Hemodynamic shear stress and its role in atherosclerosis. J Am Med Assoc 1999, 282:2035-2042.
12. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimai accumulation of low density lipopro-tein. Invest 1997, 100:2680-2690.
13. McGill HC Fatty streaks in the coronary arteries and aorta. Lab Invest 1968, 18:560-564.
14. Strong JP, McGill HC The natural history of coronary atheroscle-rosis. Am J Pathol 1962, 40:37-49.
15. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy: The Bogalusa Heart S. Am J Cardiol 1992, 70:851-858.
16. Ross R The pathogenesis of atherosclerosis TV. Engl J Med 1986, 314:488-500.
17. Fuster V, Badimon L, Badimon JJ, Chesebro JH The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250.
18. Ross R Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-226.
19. Steinberg D, Lewis A Oxidative modification of LDL and athero-genesis. Circulation 1997, 95:1062-1071.
20. Schönbeck U, Mach F, Sukhova GK, et al. Regulation of matrix me-talloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res 1997, 81:448-454.
21. Libby P Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
22. Hansson GK Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
23. Lefkovits J, Plow EF, Topol EJ Platelet Glycoprotein Ilb/IIIa recep-tors in cardiovascular medicine. N Engl J Med 1995, 332:1553-1559.
24. Ernst E, Matrai A, Marshall M Blood rheology in patients with ischemie attacks. Stroke 1988, 19:634-636.
25. Resch KL, Ernst E, Matrai A, Paulson HF Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Int Med 1992, 117:371-375.
26. Braunwald E, Antman EM, Beasley JW, et al. Committee on the management of patients with unstable angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-seg. Coll Cardiol 2002, 40:1366-1374.
27. Yang H, Pu M, Rodriguez D, et al. Ischemic and viable myocardium in patients with non-Q-wave or Q-wave myocardial infarction and left ventricular dysfunction. J Am Coll Cardiol 2004, 43:592-598.
28. Stary HC Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989, 99:119-132.
29. Solberg LA, Strong JP Risk factors and atherosclerosis lesions: a re-view of autopsy studies. Arteriosclerosis 1983, 3:187-198.
30. Vlodaver Z, Kahn HA, Neufeld HN The coronary arteries in early life in three different ethnic groups. Circulation 1979, 39:541-550.
31. Kalin MF, Zumoff B Sex hormones and coronary disease: a review of the clinical studies. Steroids 1990, 55:330-352.
32. Neufeld HN, Wagenvoort CA, Edwards JE Coronary arteries in fe-tuses, infants, juveniles and young adults. Lab Invest 1962, 11:837-844.
33. Fuster V, Badimon L, Badimon JJ, Chesebro JH The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:310-318.
34. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus Statement from the Cardiac Imaging Committee. Circulation 2005, 111:682-696.
35. Kessler KM Syndrome X: the epicardial view. J Am Coll Cardiol 1992, 19:32-33.
36. Billinger M, Kloos P, Eberli FR, et al. Physiologically assessed coro-nary collateral flow and adverse cardiac ischemie events: a follow-up study in 403 patients with coronary artery disease. J Am Coll Cardiol 2002, 40:1545-1550.
37. Kloner RA, Rezkalla SH Cardiac protection during acute myocardial infarction: where do we stand in 2004?. JAm Coll Cardiol 2004, 44:276-286.
38. Lefer DJ Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion. New Horizons 1995, 3:105-112.
39. Young JJ, Kereiakes DJ Pharmacologie reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. Rev Car-diovasc Med 2003, 4:216-227.
40. Aldrighi JM, Alecrin IN, Caldas MA, et al. Effects of estradiol on myocardial global performance index in hypertensive postmenopausal women. Gynecol Endocrinol 2004, 19:282-292.
41. Alecrin IN, Aldrighi JM, Caldas MA, et al. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunctio. Heart 2004, 90:777-781.
42. McHugh NA, Cook SM, Schairer JL, Bidgoli MM, Merrill GF Ischemia-and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen. Am J Physiol 1995, 268:H2569-H2573.
43. Delyani JA, Murohara T, Nossuli TO, Lefer AM Protection from myocardial reperfusion injury by acute administraiton of 17β-estra-diol. J Mol Cell Cardiol 1996, 28:1001-1008.
44. Hale SL, Birnbaum Y, Kloner RA beta;-estradiol, but not α-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J 1996, 132:258-262.
45. Kim YD, Lees DE Estrogen and ischemic heart disease. Chonnam J Med Sci 1996, 9:62-70.
46. Kim YD, Chen B, Beauregard J, et al. 17-beta-estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation 1996, 94:2901-2908.
47. Gorodeski GI, Levy MN, Yang T, Goldfarb J, Utian WH Beneficial effects of estrogen on cardiac stunning in female rabbits. J Soc Gynecol Invest 1999, 6:80-87.
48. Report of a WHO consultation: obesity, preventing and managing the global epidemic. World Health Organ Tech Rep Ser 2002, 894:i-xii.
49. Report of a WHO consultation: obesity, preventing and managing the global epidemic. World Health Organ Tech Rep Ser 2002, 894:1-253.
50. Flegal KM, Carroll MD, Ogden CL, Johnson CL Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc 2002, 288:1723-1727.
51. National Center for Health Statistics NHANES 1999 prevalence of overweight and obesity among adults: US, 1999 1999, US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Hyattsville, MD.
52. National Insti-tutes of Health Obes Res 1998, 6:51S-209S. Clinical guidelines on the identification evaluation treatment of overweight and obesity in adults: the evidence report.
53. Martin ML, Jensen MD Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest 1991, 88:609-613.
54. Larsson B, Bengtsson C, Bjorntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction?. Am J Epidemiol 1992, 135:266-273.
55. Armellini F, Micciolo R, Ferrari P, et al. Blood pressure, metabolic variables and adipose tissue distribution in pre and postmenopausal women. Acta Obstet Gynecol Scand 1990, 69:627-633.
56. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990, 322:882-889.
57. Pi-Sunyer FX The epidemiology of central fat distribution in relation to disease. Nutr Rev 2004, 62:S120-S126.
58. Jensen DM, Haymond MW, Rizza RA, Cryer PE, Miles JM Influ-ence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989, 83:1168-1173.
59. Ferraro R, Lillioja S, Fontvieille AM, et al. Lower sedentary meta-bolic rate in women compared with men JClin. Invest 1992, 90:780-784.
60. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mor-tality among women. N Engl J Med 1995, 333:677-685.
61. Orzano AJ, Scott JG Diagnosis and treatment of obesity in adults: an applied evidence-based review. J Am Board Fam Pract 2004, 17:359-369.
62. Grundy SM Obesity, metabolic syndrome, and cardiovascular dis-ease. J Clin Endocrinol Metabolism 2004, 89:2595-2600.
63. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Ad. Cir-culation 2002, 106:3143-3421.
64. National Center for Health Statistics NHANES IV Report 2005, http://www.cdc.gov/nchs/product/pubs/pubd/hestats/obes/obese99.htm2002.
65. Health, United States, 2003 2003, National Center for Health Statistics, Hyattsville, MD. http://www.cdc.govJnchs/hus.htm.
66. Dietz WH, Robinson TN Overweight children and adolescents. N Engl J Med 2005, 352:2100-2109.
67. CDC/NCHS, NHANES, 1999-2002. Accessed June 15,2005, from www.americanheart.org.
68. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults,1999-2002. J Am Med Assoc 2004, 291:2847-2850.
69. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey,1988-1994. Arch PediatrAdol Med 2003, 157:821-827.
70. CDC/NCHS, NHANES III (1988-1994). Accessed June 15, 2005, from http://www.americanheart.org.
71. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syn-drome among US adults Findings fom the Third National Health and Nutrition Examination. Survey. J Am Med Assoc 2002, 287:356-359.
72. McGill HC, McMahan CA, Herderick EE, et al. Origin of athero-sclerosis in childhood and adolescenceAM. J Clin Nutr 2000, 72:1307S-1315S.
73. Kannel WB Nutrition and the occurrence and prevention of cardio-vascular disease in the elderly. Nutr Rev 1988, 46:68-78.
74. Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641-646.
75. Jensen J, Nilas L, Christiansen C Influence of menopause on serum lipids and lipoproteins. Maturitas 1990, 12:321-331.
76. Ericsson S, Ericsson M, Vitols S, et al. Influence of age on the me-tabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991, 87:591-596.
77. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB Lipo-protein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61:946-951.
78. Wild RA, Alanpovic P, Givens JR, Parker IJ Lipoprotein abnormali-ties in hirsute women. Am J Obstet Gynecol 1992, 167:1813-1818.
79. Health, United States, 2003 2003, National Center for Health Statistics, Hyattsville, MD. http://www.cdc.gov/nchs/hus.htm.
80. Kannel WB, Wilson PWF, Zhang TJ The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991, 121:1268-1273.
81. Davy KP, Hall JE Obesity and hypertension: two epidemics or one?. Am J Physiol Regul Integr Comp Physiol 2004, 286:R803-R813.
82. Isles CG, Hole DJ, Hawthorne VM, Lever AF Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley Survey: comparison with men. Lancet 1992, 339:702-706.
83. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc 2003, 289:2560-2571.
84. Dittrich H, Gilpin E, Nicol P, et al. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. Am J Cardiol 1988, 62:1-7.
85. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, ,151:1141-1147.
86. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction. N Engl J Med 1998, 339:229-234.
87. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortal-ity after the first myocardial infarction. The FINMONICA Myocar-dial Infarction Register Study Group. Diabetes Care 1998, 21:69-75.
88. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess. Circulation 2000, 102:1014-1019.
89. Harris ML Summary. NIH publication number 95-1468 1995, 1-14. In: National Diabetes Data Group, Government Printing Office, Washington, DC. 2.
90. Jarrett RJ, McCartney P, Keen H The Bedford Study: ten year mor-tality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary hear. Diabetologia 1982, 22:79-84.
91. McGill HC, Strong JP, Tracy RE, McMahan CA, Oalmann MC Pathobiological determinants of atherosclerosis in Youth (PDAY) Research Group. Relation of a postmortem renal index of hyperten-sion to atherosclerosis in yo. Arterioscler Thromb Vase Biol 1995, 15:2222-2228.
92. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regula-tion and diabetic complications. Arch Intern Med 2004, 164:2090-2095.
93. Schmidt A, Stern D Hyperinsulinemia and vascular dysfunction: the role of nuclear factor-KB, yet again. Circ Res 2000, 87:722-724.
94. Verma S, Wang CH, Weisel RD, et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosigli-tazone. J Mol Cell Cardiol 2003, 35:417-419.
95. Moreno PR, Fuster V New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004, 44:2293-2300.
96. Dickinson S, Brand-Miller J Glycemie index, postprandial glycemia and cardiovascular disease. Curr Opinion Lipidol 2005, 16:69-75.
97. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001, 24:1936-1940.
98. Winer N, Sowers JR Epidemiology of diabetes. J Clin Pharmacol 2004, 44:397-405.
99. Bush TL, Comstock CW Smoking and cardiovascular mortality in women. Am J Epidemiol 1983, 118:480-488.
100. Rosenberg L, Kaufman DW, Helmrich SP, et al. Myocardial infarc-tion and cigarette smoking in women younger than 50 years of age. J Am Med Assoc 1985, 253:2965-2969.
101. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities TV. Engl J Med 1991, 324:1619-1625.
102. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute ex-cess risks of coronary heart disease among women who smoke ciga-rettes. N Engl J Med 1987, 317:1303-1309.
103. Goldenberg I, Jonas M, Tenenbaum A, et al. Current smoking, smok-ing cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 2003, 163:2301-2305.
104. Tobacco-related mortality. Fact sheet 2004, http://www.cdc.gov/tobacco.
105. The health consequences of smoking. Report of the Surgeon General 2004, CDC/NCHS.
106. Palmer JR, Rosenberg L, Shapiro S "Low yield" cigarettes and the risk of nonfatal myocardial infarction in women TV. Engl J Med 1989, 320:1569-1573.
107. Law MR, Morris JK, Wald NJ Environmental tobacco smoke expo-sure and ischémie heart disease: an evaluation of the evidence. Brit Med J 1997, 315:973-980.
108. Gupta R, Gurm H, Bartholomew JR Smokeless tobacco and cardio-vascular risk. Arch Intern Med 2004, 164:1845-1849.
109. Bolinder G, Alfredsson L, Englund A, de Faire U Smokeless tobacco use and increased cardiovascular mortality among Swedish construc-tion workers. Am J Public Health 1994, 84:399-404.
110. Barnoya J, Glantz SA Cardiovascular effects of secondhand smoke. Circulation 2005, 111:2684-2698.
111. Kaur S, Cohen A, Dolor R, Coffman CJ, Bastian LA The impact of environmental tobacco smoke on women's risk of dying from heart disease: a meta-analysis. J Womens Health (Larchmt) 2004, 13:888-897.
112. Rosenberg L, Palmer JR, Shapiro S Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990, 322:213-217.
113. Accessed June, 15, 2005, from www.who.ch/ntday/ntday98.
114. Mjos OD Lipid effects of smoking. Am Heart J 1988, 115:272-275.
115. Schoenberger JC Smoking change in relation to changes in blood pressure, weight and cholesterol. Prev Med 1982, 11:441-453.
116. Renaud S, Blache D, Dumont E, Therenon C, Wissendanger T Platelet function after cigarette smoking in relation to nicotine and carbon monoxide. Clin Pharmacol Ther 1984, 36:389-395.
117. Davis JW, Davis RF Acute effects of tobacco cigarette smoking on the platelet aggregate ratio. Am J Med Sci 1979, 278:139-143.
118. Markowe HLJ, Marmot MG, Shipley MJ, et al. Fibrinogen: a possi-ble link between social class and coronary heart disease. Br Med J 1985, 291:1312-1314.
119. Ambrose JA, Barua RS The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731-1737.
120. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YDI, Reaven GM Insulin resistance and cigarette smoking. Lancet 1992, 339:1128-1130.
121. Craig WY, Palomaki GE, Haddow JE Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. Br Med J 1989, 298:784-788.
122. Muscat JE, Harris RE, Haley NJ, Wynder EL Cigarette smoking and plasma cholesterol. Am Heart J 1991, 121:141-147.
123. Daniel M, Martin AD, Faiman C Sex hormones and adipose tissue distribution in premenopausal cigarette smokers. Int J Obesity 1992, 16:245-254.
124. Keil DP, Baron JA, Anderson JJ, Hannan MT, Felson DT Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Int Med 1992, 116:716-721.
125. Tansavatdi K, McClain B, Herrington DM The effects of smoking on estradiol metabolism. Minerva Gynecol 2004, 56:105-114.
126. Hartz AJ, Kelber S, Borkowf H, et al. The association of smoking with clinical indicators of altered sex steroids-a study of 50,145 women. Public Health Rep 1987, 102:254-259.
127. Lesko SM, Rosenberg L, Kaufman DW, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med 1985, 313:593-596.
128. Baron JA, La Vecchia C, Levi F The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990, 162:502-514.
129. Barbieri RL, McShane RM, Ryan KJ Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertil Steril 1986, 46:232-236.
130. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N Engl J Med 1986, 315:1305-1309.
131. Youth Risk Behavior Surveillance [YRBS ] MMWR 2004, 53. United States, 2003, SS2-2, CDC/NCHS, May 21.
132. Cigarette Smoking Among High School Students-11 States 1991-1997. MMWR 1999, 48. 31, CDC/NCHS, Aug.
133. Second national report on human exposure to environmental chemicals: tobacco smoke 2003, 80. CDC/NCHS.
134. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Pre-vention and the American College of Sports Medicine. J Am Med Assoc 1995, 273:402-407.
135. Britton A, McPherson K Monitoring the progress of the 2010 target for coronary heart disease mortality: estimated consequences on CHD incidence and mortality from changing prevalenc 2002, Accessed June 15, 2005from, National Heart Forum, London. http://www.americanheart.org.
136. Oguma Y, Shinoda-Tagawa T Physical activity decreases cardiovascu-lar disease risk in women: review and meta-analysis. Am J Prev Med 2004, 26:407-418.
137. Sallis JF, Patterson TL, Buono MJ, Nader PR Relation of cardiovas-cular fitness and physical activity to cardiovascular risk factors in children and adults. Am J Epidemiol 1988, 127:933-941.
138. Welk GJ, Blair SN President's Council on Physical Fitness and Sports. Physical activity protects against the health risks of obesity. Research Digest 2000, 3:1-7.
139. Okura T, Nakata Y, Tanaka K Effects of exercise intensity on physical fitness and risk factors for coronary heart disease. Obesity Res 2003, 11:1131-1139.
140. Stefanick ML, Wood PD Physical activity, lipid and lipoprotein metabolism, and lipid transport. Physical activity, fitness and health: international proceedings and consensus statement 1994, 417-431. Human Kinetics, Champaign, IL. C. Bouchard, R.J. Shephard, P.T. Ste- (Eds.).
141. Kelley GA, Kelley KS, Tran ZV Aerobic exercise and lipids and lipo-proteins in women: a meta-analysis of randomized controlled trials. J Womens Health (Larchmt) 2004, 13:1148-1164.
142. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and in-cidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991, 338:774-778.
143. Manson JE, Nathan DM, Krolewski AS, et al. A prospective study of exercise and incidence of diabetes among US male physicians. J Am Med Assoc 1992, 268:63-67.
144. Owens JF, Matthews KA, Wing RR, Kuller LH Can physical activity mitigate the effects of aging in middle aged women?. Circulation 1992, 85:1265-1270.
145. Considine RV Acute and chronic effects of exercise on leptin levels in humans. J Appl Physiol 1997, 83:3-4.
146. Colditz GA, Stampfer MJ, Willett WC, et al. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol 1986, 123:48-58.
147. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989, 64:555-559.
148. Lusis AJ, Weinreb A, Drake TA, Allayee H Genetics of atherosclerosis. Textbook of cardiovascular medicine 2002, Lippincott, Williams & Wilkins, Philadelphia. 2. E. Topol (Ed.).
149. Jee SH, Song KS, Shim WH, Kim HK, Suh I, Park JY, et al. Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography. Hum Genet 2002, 111:128-135.
150. King RA, Rotter JI, Motulsky AG The genetic basis of common diseases 2002, Oxford University Press, New York.
151. Tournier-Lasserve E New players in the genetics of stroke. N EnglJ Med 2002, 347:1711-1712.
152. Goldstein JL, Hobbs HH, Brown MS Familial hypercholesterolemia. The metabolic basis of inherited disease 1995, 1267-1282. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
153. Pajukanta P, Cargill M, Viitanen L, et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early-and late-settlement populations of Finland. Am J Hum Genet 2000, 67:1481-1493.
154. Francke S, Manraj M, Lacquemant C, et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16pl3 and replicates linkage with the meta-boli. Hum Mol Genet 2001, 10:2751-2765.
155. Broeckel U, Hengstenberg C, Mayer B, et al. A comprehensive link-age analysis for myocardial infarction and its related risk factors. Nat Genet 2002, 30:210-214.
156. Wang Q, Rao S, Shen GQ, et al. Premature myocardial infarction novel susceptibility locus on chromosome lp34-36 identified by ge-nome-wide linkage analysis. Am J Hum Genet 2004, 74:262-271.
157. Lusis AJ Atherosclerosis. Nature 2000, 407:233-241.
158. Wang X, Paigen B Quantitative trait loci and candidate genes regu-lating HDL cholesterol: a murine chromosome map. Arterioscler Thromb Vasc Biol 2002, 22:1390-1401.
159. Lusis AJ, Mar R, Pajukanta P Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004, 5:189-218.
160. Stolarz K, Staessen JA, Kawecka-Jaszcz K, et al. Genetic variation in CYP11B2 and ATlR influences heart rate variability conditional on sodium excretion. Hypertension 2004, 44:156-162.
161. Massona LF, McNeill BG The effect of genetic variation on the lipid response to dietary change. Curr Opin Lipidol 2005, 16:61-67.
162. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A Genetics of HDL regulation in humans. Curr Opin Lipidol 2003, 14:273-279.
163. Glomset JA The metabolic role of lecithin cholesterol acyltransferase: perspectives from pathology. Adv Lipid Res 1973, 11:1-65.
164. Hovingha GK, de Groota E, van-der Steega W, et al. Inherited dis-orders of HDL metabolism and atherosclerosis. Curr Opinion Lipidol 2005, 16:139-145.
165. Herrington D, Potvin-Klein K Pharmacogenetics of estrogen re-placement therapy. J Appl Physiol 2001, 91:2776-2784.
166. Henrynk MH, Fuqua SAW Estrogen receptor mutations in human disease. Endocrine Rev 2004, 25:869-898.
167. Herrington DM, Howard TD ER-alpha variants and the cardiovas-cular effects of hormone replacement therapy. Pharmacogenomics 2003, 4:269-277.
168. Fraser GE, Strahan TM, Sabate J, Beeson L, Kissinger D Effects of traditional coronary risk factors on rates of incident coronary events in a low risk population. Circulation 1992, 86:406-413.
169. Hunt BJ The relation between abnormal hemostatic function and the progression of coronary disease. Curr Opin Cardiol 1990, 5:758-765.
170. Sesso HD, Kawachi I, Vokonas PS, Sparrow D Depression and the risk of coronary heart disease in the Normative Aging Study. Am J Cardiol 1998, 82:851-856.
171. Barth J, Schumacher M, Herrmann-Lingen C Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004, 66:802-813.
172. Vinkers DJ, Stek ML, Gussekloo J, Van Der Mast RC, Westendorp RG Does depression in old age increase only cardiovascular mortality? The Leiden 85-plus Study. Int J Geriatr Psychiatry 2004, 19:852-857.
173. Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004, 164:289-298.
174. Wolff B, Grabe HJ, Volzke H, et al. Relation between psychological strain and carotid atherosclerosis in a general population. Heart 2005, 91:460-464.
175. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk fac-tor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004, 66:305-315.
176. Van Meile JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and car-diovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
177. Joynt KE, Whellan DJ, O'Connor CM Depression and cardiovascu-lar disease: mechanisms of interaction. Bio Psychiatry 2003, 54:248-261.
178. Sauer WH, Berlin JA, Kimmel SE Selective serotonin reuptake in-hibitors and myocardial infarction. Circulation 2001, 104:1894-1898.
179. Sauer WH, Berlin JA, Kimmel SE Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003, 108:32-36.
180. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depres-sion and low perceived social support on clinical events after myocar-dial infarction: the Enhancing Recovery in Coronary Heart Dis. J Am Med Assoc 2003, 289:3106-3116.
181. Herd JA Cardiovascular response to stress. Physiol Rev 1991, 71:305-330.
182. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning in-crease in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987, 316:1514-1518.
183. Willich SN, Tofler GH, Brezinski DA, et al. Platelet α2 adrenoceptor characteristics during the morning increase in platelet aggregability. Eur Heart J 1992, 13:550-555.
184. Panza JA, Epstein SE, Quyyumi AA Circadian variation in vascular tone and its relation to sympathetic vasoconstrictor activity. N Engl J Med 1991, 325:986-990.
185. Manfredini R, Gallerani M, Portaluppi F, Fersini C Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and ar-rhythmic events to blood pressure rhythms. Ann N Y Acad Sci 1996, 783:141-158.
186. Ballinger SE, Walker WL Not THE change of life: breaking the menopause taboo 1987, Penguin, Ringwood, Victoria, Australia.
187. Ballinger S Stress as a factor in lowered estrogen levels in the early postmenopause. Ann NY Acad Sci 1990, 592:95-113.
188. Woods NF, Derby GK, Most A Stressful life events and perimen-strual symptoms. J Hum Stress 1982, 8:23~31.
189. Stratton JR, Levy WC, Caldwell JH, et al. Effects of aging on cardio-vascular responses to parasympathetic withdrawal. J Am Coll Cardiol 2003, 41:2077-2083.
190. Tse HF, Oral H, Pelosi F, et al. Effect of gender on atrial electro-physiologic changes induced by rapid atrial pacing and elevation of atrial pressureJ. Cardiovasc Electrophysiol 2001, 12:986-989.
191. Malloy KJ, Bahinski A Cardiovascular disease and arrhythmias: unique risks in women J. Gend Specif Med 1999, 2:37-44.
192. Pham TV, Rosen MR Sex, hormones, and repolarization. Cardiovasc Res 2002, 53:740-751.
193. Carnethon MR, Anthony MS, Cascio WE, et al. A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: the atherosclerosis risk in communities study. Ann Epidemiol 2003, 13:530-536.
194. Hsia J, Aragaki A, Bloch M, et al. Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observa-tional Study. Am J Cardiol 2004, 93:673-678.
195. National Institutes of Health Chartbook on cardiovascular, lung and blood diseases 1992, May, US Department of Health and Human Services, Bethesda, MD.
196. Weinblatt E, Shapiro S, Frank CW Prognosis of women with newly diagnosed coronary heart disease: a comparison with course of disease among men. Am J Public Health 1973, 63:577-593.
197. Murabito JM, Evans JC, Larson MG, Levy D Prognosis after the onset of coronary heart disease: an investigation of differences in outcome between the sexes according to initial coronary disease pre-se. Circulation 1993, 88:2548-2555.
198. Hurst W The heart, arteries and veins 2002, McGraw-Hill, New York. 10.
199. Cunningham MA, Lee TH, Cook EF, et al. The effect of gender on the probability of myocardial infarction among emergency depart-ment patients with acute chest pain: a report from the Multicenter Che. Intern Med 1989, 4:392-398.
200. Robinson K, Conroy RM, Mulcahy R, Hickey N Risk factors and in hospital course of first episode of myocardial infarction or acute coro-nary insufficiency in women. J Am Coll Cardiol 1988, 11:932-936.
201. Maynard C, Litwin PE, Martin JS, Weaver WD Gender differences in the treatment and outcome of acute myocardial infarction: results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med 1992, 152:972-976.
202. Lerner DJ, Kannel WB Patterns of coronary heart disease morbidity and mortality in the sexes. A 26 year follow-up of the Framingham population. Am Heart J 1986, 111:383-390.
203. Basaria S, Dobs AS Treatment of hyperlipidemia in women. Int J Fertil Womens Med 2000, 45:22-33.
204. Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD Comparison of presentation, treatment, and outcome of acute myo-cardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Regi. Am J Cardiol 1996, 78:9-14.
205. Goldberg RJ, O'Donnell C, Yarzebski J, et al. Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. Am Heart J 1998, 136:189-195.
206. Alexander KP, Peterson ED Medical and surgical management of coro-nary artery disease in women. Am J Manag Care 2001, 7:951-956.
207. Kyker KA, Limacher MC Gender differences in the presentation and symptoms of coronary artery disease. Curr Womens Health Rep 2002, 2:115-119.
208. DeVon HA, Zerwic JJ The symptoms of unstable angina: do women and men differ?. Nurs Res 2003, 52:108-118.
209. Patel H, Rosengren A, Ekman I Symptoms in acute coronary syn-dromes: does sex make a difference?. Am Heart J 2004, 148:27-33.
210. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987, 9:473-482.
211. Tunsta11-Pedoe H, Morrison C, Woodward M, Fitzpatrick B, Watt G Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985-1991: presentation, diagnosis, treatment, and 2. Circulation 1996, 93:1981-1992.
212. Rosengren A, Wallentin L, Gitt AK, et al. Sex, age, and clinical pre-sentation of acute coronary syndromes. Eur Heart J 2004, 25:663-670.
213. Douglas PS, Ginsburg GS The evaluation of chest pain in women. N Engl J Med 1996, 334:1311-1315.
214. Rosen AB, Tsai JS, Downs SM Variations in risk attitude across race, gender, and education. Med Decis Making 2003, 23:511-517.
215. Bugiardini R, Bairey-Merz CN Angina with"normal" coronary ar-teries: a changing philosophy. J Am Med Assoc 2005, 293:477-484.
216. Hutchinson SJ, Poole-Wilson PA, Henderson AH Angina with normal coronary arteries: a review. Q J Med 1989, 72:677-688.
217. Ockene IS, Shay MJ, Alpert JS, Weiner BH, Dalen JE Unexplained chest pain in patients with normal coronary arteriograms. N Engl J Med 1980, 303:1249-1252.
218. Leppert J, Aberg H, Ringqvist F, Sorensson S Raynaud's phenome-non in a female population: prevalence and association with other conditions. Angiology 1987, 38:871-877.
219. Kronenberg F Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
220. Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (TIMI-IIIA Trial). Am J Cardiol 1994, 74:531-537.
221. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lun. Circulation 2004, 109:2993-2999.
222. Theres H, Maier B, Gothe RM, et al. Influence of gender on treat-ment and short-term mortality of patients with acute myocardial in-farction in Berlin. Z Kardiol 2004, 93:954-963.
223. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute. Am Heart J 2004, 147:133-139.
224. Ayanian JZ, Epstein AM Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991, 325:222-225.
225. Steingart RM, Packer M, Hamm P, et al. Sex differences in the man-agement of coronary artery disease. N Engl J Med 1991, 325:226-230.
226. Chirikos TN, Nickel JL Work disability from coronary heart disease in women. Women Health 1984, 9:55-74.
227. Todaro JF, Shen BJ, Niaura R, Tilkemeier PL, Roberts BH Do men and women achieve similar benefits from cardiac rehabilitation?. J Cardiopulm Rehabil 2004, 24:45-51.
228. Regitz-Zagrosek V, Lehmkuhl E, Lehmkuhl HB, Hetzer R Gender aspects in heart failure: pathophysiology and medical therapy. Arch Mal Coeur Vaiss 2004, 97:899-908.
229. Stromberg A, Martensson J Gender differences in patients with heart failure. EurJ Cardiovascular Nursing 2003, 2:7-18.
230. Lund LH, Mancini D Heart failure in women. Med Clin North Am 2004, 88:1321-1345.
231. McGill HC, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vase Biol 1997, 17:95-106.
232. Holman RL, McGill HC, Strong JP, Geer JC The natural history of atherosclerosis. The early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Pathol 1958, 2:209-235.
233. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA Distribution of coronary and aortic atherosclerosis by geographic lo-cation, race, and sex. Lab Invest 1968, 18:509-526.
234. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fo-gelman AM Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
235. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003, 290:2292-2300.
236. Ohta T, Hattori S, Murakami M, Nishiyama S, Matsuda I Age and sex related differences in lipoproteins containing apoprotein A-I. Arteriosclerosis 1989, 9:90-95.
237. Bush TL The epidemiology of cardiovascular disease in postmeno-pausal women. Ann NY Acad Sci 1990, 592:263-271.
238. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravinkar V, Sacks FM Effects of postmenopausal estrogen replacement on the concentra-tions and metabolism of plasma lipoproteins. N Engl J Med 1991, 325:1196-1204.
239. Sacks FM, McPherson R, Walsh BW Effect of postmenopausal es-trogen replacement on plasma Lp (a) lipoprotein concentrations. Arch Int Med 1994, 154:1106-1110.
240. Bruckert E, Turpin G Estrogens and progestins in postmenopausal women, influence on lipid parameters and cardiovascular risk. Horm Res 1995, 43:100-103.
241. Haines CJ, Chung TK, Masarei JR, Tomlinson B, Lau JT An exami-nation of the effect of combined cyclical hormone replacement ther-apy on lipoprotein (a) and other lipoproteins. Atherosclerosis 1996, 119:215-222.
242. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH Effect of hormone replacement therapy on lipoprotein (a)and lipid levels in postmeno-pausal women. Influence of various progestogens and duration of therapy. Arch Int Med 1996, 156:1693-1700.
243. Mehilli J, Ndrepepa G, Kastrati A, et al. Gender and myocardial sal-vage after reperfusion treatment in acute myocardial infarction. J Am Coll Cardiol 2005, 45:828-831.
244. Zhao X, Eghbali-Webb M Gender-related differences in basal and hypoxia-induced activation of signal transduction pathways control-ling cell cycle progression and apoptosis, in cardi. Endo-crine 2002, 18:137-145.
245. Curl CL, Wendt IR, Canny BJ, Kotsanas G Effects of ovariectomy and 17 beta-oestradiol replacement on [Ca21 Ji in female rat cardiac myocytes. Clin Exp Pharmacol Physiol 2003, 30:489-494.
246. Jovanovic S, Jovanovic A, Shen WK, Terzic A Low concentrations of 17-beta-estradiol protect single cardiac cells against metabolic stress-induced Ca21 loading. J Am Coll Cardiol 2000, 36:948-952.
247. Anderson SE, Kirkland DM, Beyschau A, Cala PM Acute effects of 17β-estradiol on myocardial pH, Nal, and Ca21 and ischemia-reperfusion injury. Am J Physiol Cell Physiol 2005, 288:C57-C64.
248. Pelzer T, Loza PA, Hu K, et al. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocar-dial infarction. Circulation 2005, 111:1492-1498.
249. Kannel WB, Hjortland MC, McNamara PM, Gordon T Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976, 85:447-452.
250. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999, 159:1061-1066.
251. Colditz GA, Willett WC, Stampfer MJ, et al. A prospective study of age at menarche, parity, age at first birth and coronary heart disease in women. Am J Epidemiol 1987, 126:861-870.
252. LaVecchia C, Decarli A, Franceschi S, et al. Menstrual and reproduc-tive factors and risk of myocardial infarction in women under 55 years of age. Am J Obstet Gynecol 1987, 157:1108-1112.
253. The Writing Group for the PEPI Trial Effects of estrogen or estro-gen/progestin regimens on heart disease risk factors in postmeno-pausal women. The Postmenopausal Estrogen/Progestin Interven-tio. J Am Med Assoc 1995, 273:199-208.
254. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis trial research group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-control. Ann Intern Med 2001, 135:939-953.
255. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000, 132:689-696.
256. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of es-trogen replacement on the progression of coronary-artery atheroscle-rosis. N Engl J Med 2000, 343:522-529.
257. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estro-gen plus progestin in healthy postmenopausal women: principal re-su. J Am Med Assoc 2002, 288:321-333.
258. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initia-tive Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative. J Am Med Assoc 2004, 291:1701-1712.
259. McDonnell DP The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Can-cer Res 2005, 11:871s-877s.
260. Rubanyi GM, Kauser K, Johns A Role of estrogen receptors in the vascular system. Vascul Pharmacol 2002, 38:81-88.
261. Nuedling S, Karas RH, Mendelsohn ME, et al. Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett 2001, 502:103-108.
262. Forster C, Kietz S, Hultenby K, Warner M, Gustafsson JA Charac-terization of the ER beta mouse heart. Proc Natl Acad Sci U S A 2004, 101:14234-14239.
263. Bjornstrom L, Sjoberg M Mechanisms of estrogen receptor signal-ing: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005, 19:833-842.
264. Hisamoto K, Bender JR Vascular cell signaling by membrane estro-gen receptors. Steroids 2005, 70:382-387.
265. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor al-pha signaling in the transcriptional control of energy metabolism in car. Mol Cell Biol 2004, 24:9079-9091.
266. Gorodeski GI Aging and estrogen effects on transcervical-transvaginal epithelial permeability. J Clin Endocrinol Metab 2005, 90:345-351.
267. Gorodeski GI Epidemiology and risk factors for cardiovascular dis-ease in postmenopausal women. Baillieres Best Pract Res Clin Obstet Gynecol 2002, 16:329-357.
268. National Institues of Health The WHI legacy to future generations of women: update on scientific contributions 2006, Feb 28-March 1, NIH, Bethesda, MD.
269. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003, 138:1-9.
270. Moria M, Tsukaharab F, Yoshiokac T, Irieb K, Ohtaa H Suppression by 17β-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sciences 2004, 75:599-609.
271. Bailey MS, Curtis AB The effects of hormones on arrhythmias in women. Curr Womens Health Rep 2002, 2:83-88.
272. Christ M, Seyffart K, Tillmann HC, Wehling M Hormone replace-ment in postmenopausal women: impact of progestogens on auto-nomie tone and blood pressure regulation. Menopause 2002, 9:127-136.
273. Ganger KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991, 338:839-842.
274. Lobo RA Cardiovascular implications of estrogen replacement ther-apy. Obstet Gynecol 1990, 75:18S-25S.
275. Kadish AH, Greenland P, Limacher MC, et al. Estrogen and proges-tin use and the QT interval in postmenopausal women. Ann Nonin-vasive Electrocardiol 2004, 9:366-374.
276. Sugishita K, Li F, Su Z, Barry WH Anti-oxidant effects of estrogen reduce [Ca21]i during metabolic inhibition. J Mol Cell Cardiol 2003, 35:331-336.
277. Hamilton KL, Gupta S, Knowlton AA Estrogen and regulation of heat shock protein expression in female cardiomyocytes: cross-talk with NF kappa B signaling. J Mol Cell Cardiol 2004, 36:577-584.
278. Patten RD, Pourati I, Aronovitz MJ, et al. 17β-estradiol reduces car-diomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004, 95:692-699.
279. Babiker FA, De Windt LJ, van Eickels M, et al. 17β-estradiol antago-nizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-depe. Circulation 2004, 109:269-276.
280. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/Progestin Replacem. J Am MedAssoc 1998, 280:605-613.
281. Shlipak MG, Chaput LA, Vittinghoff E, et al. Heart and Estrogen/ Progestin Replacement Study Investigators. Lipid changes on hor-mone therapy and coronary heart disease events in the Heart and Estrogen/P. Am Heart J 2003, 146:870-875.
282. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch In-tern Med 2006, 166:357-365.
283. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomark-ers, hormone replacement therapy, and incident coronary heart dis-ease: prospective analysis from the Women's Health Initiative obser-vat. J Am Med Assoc 2002, 288:980-987.
284. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. JAm Coll Cardiol 2000, 36:1797-1802.
285. Koh KK, Son JW, Ahn JY, et al. Non-lipid effects of statin on hyper-cholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a ste. Coron Artery Dis 2001, 12:305-311.
286. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 68 years of hormone ther-apy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002, 288:49-57.
287. Herrington DM, Vittinghoff E, Lin F, et al. The HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circula-tion 2002, 105:2962-2967.
288. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
289. Shapiro S Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003, 6:302-310.
290. Machens K, Schmidt-Gollwitzer K Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?. Human Reproduction 2003, 18:1992-1999.
291. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Wom-en's Health Initiative Observational Study. Circulation 2005, 111:1462-1470.
292. Stampfer MJ, Colditz GA Estrogen replacement therapy and coro-nary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
293. Grodstein F, Manson JE, Stampfer MJ Hormone therapy and coro-nary heart disease: the role of time since menopause and age at hor-mone initiation JWomens. Health 2006, 15:35-44.
294. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S The direct antiatherogenic effect of estrogen is present , absent or reversed, depending on the state of the arterial endothelium. A time course study in chol. Circulation 1999, 100:1727-1733.
295. Williams JK, Anthony MS, Honore EK, et al. Regression of athero-sclerosis in female monkeys. Arterioscler Thromb Vase Biol 1995, 15:827-836.
296. Actams MR, Register TC, Golden DL, Wagner JD, Williams JK Medroxyprogesterone acetate antagonizes inhibitory effects of conju-gated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vase Biol 1997, 17:217-221.
297. Clarkson TB, Anthony MS, Jerome CP Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998, 83:721-726.
298. Clarkson TB, Anthony MS, Morgan TM Inhibition of postmeno-pausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001, 86:41-47.
299. Mikkola TS, Clarkson TB Estrogen replacement therapy, atheroscle-rosis, and vascular function. Cardiovasc Res 2002, 53:605-619.
300. Herrington DM, Espeland MA, Crouse JR, et al. Estrogen re-placement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vase Biol 2001, 21:1955-1961.
301. Stampfer M Hormones and heart disease: do trials and observational studies address different questions?. Int J Epidemiol 2004, 33:454-455.
302. Grodstein F, Manson JE, Stampfer MJ Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med 2001, 135:1-8.
303. Stampfer MJ Postmenopausal hormones and CHD: update from the Nurses' Health Study. The 15th Annual meeting of the North American Menopause Society 2004.
304. Humphrey LL, Chan BK, Sox HC Postmenopausal hormone re-placement therapy and the primary prevention of cardiovascular dis-ease. Ann Intern Med 2002, 137:273-284.
305. Michels KB Hormone replacement therapy in epidemiologic studies and randomized clinical trials-are we checkmate?. Epidemiology 2003, 14:3-5.
306. Scarabin PY, Oger E, Plu-Bureau G Estrogen Thrombo-Embo-lism Risk Study Group. Differential association of oral and transder-mal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362:428-432.
307. Kaplan JR, Manuck SB, Anthony MS, Clarkson TB Premenopausal social status and hormone exposure predict postmenopausal athero-sclerosis in female monkeys. Obstet Gynecol 2002, 99:381-388.
308. Clarkson TB, Appt SE MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids 2003, 68:941-951.
309. Nieto FJ Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century. Am J Public Health 1999, 89:292-294.
310. Lefkowitz RJ Willerson JT Prospects for cardiovascular research. J Am Med Assoc 2001, 285:581-587.
311. Magnus P, Beaglehole R The real contribution of the major risk fac-tors to the coronary epidemics: time to end the "only-50%" myth. Arch Intern Med 2001, 161:2657-2660.
312. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N. Engl J Med 2002, 347:1557-1565.
313. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulner-able patient. A call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
314. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulner-able patient. A call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772-1778.
315. Mosca L Heart disease prevention in women. Circulation 2004, 109:e158-e160.
316. Kwok Y, Kim C, Grady D, Segal M, Redberg R Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999, 83:660-666.
317. Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998, 32:1657-1664.
318. McTigue KM, Harris R, Hemphill B, et al. Screening and interven-tions for obesity in adults: summary of the evidence for the US Pre-ventive Services Task Force. Ann Intern Med 2003, 139:933-949.
319. Goldstein DJ Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
320. Garrow J Christmas factor and snacking. Lancet 2000, 355:8.
321. Karlsson J, Sjostrom L, Sullivan M Swedish obese subjects (SOS) -an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric. Int J Obes Relat Metab Disord 1998, 22:113-126.
322. Karason K, Lindroos AK, Stenlof K, Sjostrom L Relief of cardiore-spiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med 2000, 160:1797-1802.
323. Skender ML, Goodrick GK, Del Junco DJ, et al. Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions JAm. Diet Assoc 1996, 96:342-346.
324. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg 1990, 211:419-427.
325. Ashley S, Bird DL, Sugden G, Royston CM Vertical banded gastro-plasty for the treatment of morbid obesity. Br J Surg 1993, 80:1421-1423.
326. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a sys-tematic review and meta-analysis. J Am Med Assoc 2004, 292:1724-1737.
327. Howard BV, Manson JE, Stefanick ML, et al. Low-fat dietary pat-tern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. J Am Med Assoc 2006, 295:39-49.
328. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: The Women's Health Initiative Ran-domized Controlled Dietary Modification Trial J Am Med. Assoc 2006, 295:655-666.
329. Bouchard C Physical activity and prevention of cardiovascular diseases: potential mechanisms. Physical activity and cardiovascular health 1997, 48-56. Human Kinetics, Champaign, IL. A.S. Leon (Ed.).
330. Press V, Freestone I, George CF Physical activity: the evidence of benefit in the prevention of coronary heart disease. Q J Med 2003, 96:245-251.
331. Morris JN, Everitt MG, Pollard R, Chave SPW, Semmence AM Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet 1980, 2:1207-1210.
332. Lee IM, Hsieh CC, Paffenbarger RS Exercise intensity and longevity in men: Harvard Alumni Health Study. J Am Med Assoc 1995, 273:1179-1184.
333. American College of Sports Medicine Guidelines for exercise testing and prescription 2000, Lippincott, Williams & Wilkins, Philadelphia.
334. Hagberg JM, Park JJ, Brown MD The role of exercise training in the treatment of hypertension. Sports Med 2000, 30:193-206.
335. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coro-nary heart disease in women. N Engl J Med 1999, 341:650-658.
336. Kushi LH, Fee RM, Folsom AR, et al. Physical activity and mortality in postmenopausal women. J Am Med Assoc 1997, 277:1287-1292.
337. Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE Physical activity and coronary heart disease in women: is"no pain, no gain" passé?. J Am MedAssoc 2001, 285:1447-1454.
338. Albert CM, Mittleman MA, Chae CU, et al. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 2000, 343:1355-1361.
339. Shaper AG, Wannamethee G, Walker M Physical activity, hyperten-sion and risk of heart attack in men without incidence of ischaemic heart disease. J Hum Hypertens 1994, 8:3-10.
340. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
341. Lindstrom J, Louheranta A, Mannelin M, et al. Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26:3230-3236.
342. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
343. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003, 163:2006-2010.
344. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109:672-693.
345. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J Am MedAssoc 1986, 256:2835-2838.
346. Castelli WP, Anderson K, Wilson PWF, Levy D Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992, 2:23-28.
347. Bass KM, Newschaffer CJ, Klag MJ, Bush TL Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209-2216.
348. Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cho-lesterol level: a metaanalysis of population. J Cardiovasc Risk 1996, 3:213-219.
349. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a) , and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 2000, 283:1845-1852.
350. Miettinen TA, Pyorala K, Olsson AG, et al. For the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findin. Circulation 1997, 96:4211-4218.
351. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
352. Lewis SJ, Sacks FM, Mitchell JS, et al. For the CARE Investigators. Effect of pravastatin on cardiovascular events in women after myocar-dial infarction: the cholesterol and recurrent events (CARE). J Am Coll Cardiol 1998, 32:140-146.
353. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women J. Worn-ens Health Gend Based Med 2001, 10:971-981.
354. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
355. LaRosa JC, He J, Vupputuri S Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J Am Med Assoc 1999, 282:2340-2346.
356. Jick SS, Bradbury BD Statins and newly diagnosed diabetes. BrJ Clin Pharmacol 2004, 58:303-309.
357. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567-572.
358. McKenney JM, Proctor JD, Harris S, Chinchili VM A comparison of the efficacy and toxic effects of sustained Vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc 1994, 271:672-677.
359. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in pa-tients with hypercholesterolemia. Am J Cardiol 1994, 73:339-345.
360. Jacobson TA, Jokubaitis LA, Amorosa LF Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994, 96:64S-68S.
361. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, anti-oxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
362. Carlson LA, Rosenhamer G Reduction of mortality in the Stock-holm Ischaemic Heart Disease Secondary Prevention Study by com-bined treatment with clofibrate and nicotinic acid. Acta Med Scand 1998, 223:405-418.
363. BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycérides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (. Circulation 2000, 102:21-27.
364. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabe-tes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001, 357:905-910.
365. Meagher EA Addressing cardiovascular disease in women: focus on Dyslipidemia. J Am Board Fam Pract 2004, 17:424-437.
366. Brown BG, Zambon A, Poulin D, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998, 81:52B-59B.
367. Pelton PD, Patel M, Demarest KT Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr Top Med Chem 2005, 5:265-282.
368. Bruemmer D, Blaschke F, Law RE New targets for PPARgamma in the vessel wa11: implications for restenosis. Int J Obes Relat Metab Disord 2005, 29:S26-S30.
369. Gunzerath L, Faden V, Zakhari S, Warren K National Institute on Alcohol Abuse and Alcoholism report on moderate drinking. Alcohol Clin Exp Res 2004, 28:829-847.
370. Howard AA, Arnsten JH, Gourevitch MN Effect of alcohol con-sumption on diabetes mellitus: a systematic review. Ann Intern Med 2004, 140:211-219.
371. Kroenke CH, Chu N-F, Rifai N, et al. A cross-sectional study of al-cohol consumption patterns and biologic markers of glycemic control among 459 women. Diabetes Care 2003, 26:1971-1978.
372. Rimm EB, Chan J, Stampfler MJ, Colditz GA, Willett WC Prospective study of cigarette smoking, alcohol use and the risk of diabetes in men. BMJ 1995, 310:555-559.
373. Wannamethee SG, Camargo CA, Manson JE, Willett WC, Rimm EB Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch Intern Med 2003, 163:1329-1336.
374. Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women. J Am Med Assoc 2002, 287:2559-2562.
375. Corrao G, Rubbiai L, Bagnardi V, Zambon A, Poikolainen K Alco-hol and coronary heart disease: a meta-analysis. Addiction 2000, 95:1505-1523.
376. Hines LM, Rimm EB Moderate alcohol consumption and coronary heart disease: a review. Postgrad Med J 2001, 77:747-752.
377. Rotondo S, DiCastelnuovo A, de Gaetano G The relationship be-tween wine consumption and cardiovascular risk: from epidemiologi-cal evidence to biological plausibility. Ital Heart J 2001, 2:1-8.
378. Murray RP, Connett JE, Tyas SL, et al. Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function?. Am J Epidemiol 2002, 155:242-248.
379. Rehm J, Sempos CT, Trevisan M Average volume of alcohol con-sumption, patterns of drinking and risk of coronary heart disease-a review. J Cardiovasc Risk 2003, 10:15-20.
380. Sillanaukee P, Koivula T, Jokela H, Pitkajarvi T, Seppa K Alcohol consumption and its relation to lipid-based cardiovascular risk factors among middle-aged women. Atherosclerosis 2000, 152:503-510.
381. Baer DJ, Judd JT, Clevidence BA, et al. Moderate alcohol consump-tion lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet. AmJ Clin Nutr 2002, 75:593-599.
382. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003, 348:109-118.
383. De Oliveira E, Silva ER, Foster D, McGee HM, et al. Alcohol consumption raises HDL cholesterol by increasing the transport rate of apolipoproteins AI and AIL. Circulation 2000, 102:2347-2352.
384. Serafini M, Laranjinha JA, Almeida LM, Maiani G Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans JNutr. Bio-chem 2000, 11:585-590.
385. Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000, 343:530-537.
386. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association be-tween cardiovascular outcomes and antihypertensive drug treatment in older women. J Am MedAssoc 2004, 292:2849-2859.
387. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
388. Cheng AW, Miller ML, Morris M, et al. A stochastic model of the long range financial status of the OASDI program. Actuarial study no. 117 2004, publication no. 11-11543, Social Security Administration, Baltimore.
389. Olshansky SJ, Hayflick L, Carnes BA Position statement on human aging. J Gerontol Biol Sci 2002, 57A:B292-B297.
390. Allard M, Lebre V, Robine JM, Calment J Jeanne Calment:from van Gogh's time to ours; 122 extraordinary years 1998, WH Freeman, New York.
391. Tobert JA Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003, 2:517-526.